Conclusion At a nickel a share, investment in t
Post# of 30028
(Total Views: 467)
Posted On: 04/11/2018 4:49:33 PM
Re: FiggyPiggy #26557
Conclusion
At a nickel a share, investment in the Amarantus portfolio is volatile but in the medium term has an enticing risk-reward profile. Right now there are too many unknowns to invest time in modeling if you're not a super computer, and with the pace of developments, any recommendations could soon be outdated. At this point, we would advise you to put this on your watch-list for the next few months and make your decision to invest or not after key announcements are made. Still, we couldn’t blame you for wading in under dime, or a quarter for that matter. The quality of management the portfolio company is able to attract to Elto Pharma or other subsidiaries will speak volumes as to the assets prospects and the viability of the business plan. Keep your eye on this one.
At a nickel a share, investment in the Amarantus portfolio is volatile but in the medium term has an enticing risk-reward profile. Right now there are too many unknowns to invest time in modeling if you're not a super computer, and with the pace of developments, any recommendations could soon be outdated. At this point, we would advise you to put this on your watch-list for the next few months and make your decision to invest or not after key announcements are made. Still, we couldn’t blame you for wading in under dime, or a quarter for that matter. The quality of management the portfolio company is able to attract to Elto Pharma or other subsidiaries will speak volumes as to the assets prospects and the viability of the business plan. Keep your eye on this one.
(5)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼